Clopidogrel is the preferred P2Y12 antagonist in patients with stable CAD undergoing PCI but it is also commonly prescribed in ACS patients deemed not suitable for potent DAPT due to increased bleeding risk. Here, P2RY12 is linked to coronary artery disorder.